Dr Nigel Whittle
With a biochemistry degree from Oxford and a PhD in the discovery of oncogenes, Nigel started work in the embryonic biotechnology industry to help bring some amazing discoveries into the clinic, first at Genentech Inc in the US, and then at Celltech and later Cantab Pharmaceuticals in the UK. He later set up his own successful life science consultancy before joining Plextek to build their medical and healthcare business, working with a range of talented people in innovative medical device organisations.
Latest articles
The first self-administered B-cell therapy for patients with relapsing forms of MS
Novartis receives European and UK licence for Kesimpta®▼(ofatumumab) Ofatumumab is a self-administered targeted B-cell depleting treatment option for adult patients living with relapsing forms of...
MHRA new advice on possible link between COVID-19 Vaccine AstraZeneca and blood clots
The benefits of vaccination continue to outweigh any risks but the MHRA advises careful consideration be given to people who are at higher risk...
Thousands of patients set to benefit from five-minute breast cancer treatment
An injection that cuts the amount of time breast cancer patients spend in hospital from two and a half hours to as little as...
Popular articles
New Normal, New Thinking: Life Post COVID-19
New thinking will be required to adapt to the new normal life post COVID-19. I hate to start this article on a negative note, but...
The first self-administered B-cell therapy for patients with relapsing forms of MS
Novartis receives European and UK licence for Kesimpta®▼(ofatumumab) Ofatumumab is a self-administered targeted B-cell depleting treatment option for adult patients living with relapsing forms of...
MHRA new advice on possible link between COVID-19 Vaccine AstraZeneca and blood clots
The benefits of vaccination continue to outweigh any risks but the MHRA advises careful consideration be given to people who are at higher risk...
Study shows anti-parasitic drug ivermectin kills coronavirus within 48 hours
A collaborative study led by the Monash Biomedicine Discovery Institute (BDI) with the Peter Doherty Institute of Infection and Immunity (Doherty Institute), a joint...
Nurofen launches a 24 hour ibuprofen pain relief patch
Nurofen announces the launch of the UK’s only 24 hour clinically proven pain relief patch containing ibuprofen. Despite body pain being among the most commonly...